文献速递妇科

紫杉醇/卡铂/贝伐珠单抗、紫杉醇/卡铂/替西罗莫司或伊沙匹隆/卡铂/贝伐珠单抗一线治疗晚期/复发性子宫内膜癌的II期研究

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2018-05-24

这项随机II期试验将349例化疗初治的晚期/复发性子宫内膜癌患者随机分配至紫杉醇/卡铂联合贝伐珠单抗组、紫杉醇/卡铂联合替西罗莫司组或伊沙匹隆/卡铂联合贝伐珠单抗组,以GOG209试验中紫杉醇/卡铂组患者为历史对照。主要终点无进展生存期在任何实验组均未较历史对照显著延长;总生存期仅在紫杉醇/卡铂联合贝伐珠单抗组显著延长。未发现新的安全性信号。

要点

  • 349例晚期/复发性子宫内膜癌患者随机接受三种含新药方案之一。
  • 无进展生存期在所有实验组均未较历史对照显著延长。
  • 总生存期仅在紫杉醇/卡铂联合贝伐珠单抗组较历史对照显著延长。

核心结论

  • 与历史对照相比,任何实验组的无进展生存期均未显著延长。

研究设计与样本

  • 随机II期试验,纳入化疗初治的III/IVA期(可测量病灶)及IVB期或复发性(有或无不可测量病灶)子宫内膜癌患者349例,随机分配至紫杉醇/卡铂联合贝伐珠单抗组、紫杉醇/卡铂联合替西罗莫司组或伊沙匹隆/卡铂联合贝伐珠单抗组,以GOG209试验紫杉醇/卡铂组患者为历史对照,主要终点为无进展生存期。

主要发现

  • 无进展生存期在任何实验组均未较历史对照显著延长(p > 0.039);实验组1、2、3相对对照的治疗风险比(92% CI)分别为0.81(0.63-1.02)、1.22(0.96-1.55)和0.87(0.68-1.11)。
  • 各实验组缓解率相似,分别为60%、55%和53%。
  • 相对历史对照,总生存期(截尾于36个月)在实验组1显著延长(p < 0.039),实验组2和3未显著延长;风险比(92% CI)分别为0.71(0.55-0.91)、0.99(0.78-1.26)和0.97(0.77-1.23)。
  • 未发现新的安全性信号。
  • 按组织学类型描述了常见突变及错配修复蛋白缺失率,并识别了替西罗莫司和贝伐珠单抗的潜在预测生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Paclitaxel and carboplatin (PC) is a standard initial therapy for advanced endometrial cancer. We evaluated the efficacy and tolerability of incorporating three novel agents into initial therapy. METHODS: In this randomized phase II trial, patients with chemotherapy-naïve stage III/IVA (with measurable disease) and stage IVB or recurrent (with or without measurable disease) endometrial cancer were randomly assigned to treatment with PC plus bevacizumab (Arm 1), PC plus temsirolimus (Arm 2) or ixabepilone and carboplatin (IC) plus bevacizumab (Arm 3). The primary endpoint was progression-free survival (PFS). Comparable patients on the PC Arm of trial GOG209 were used as historical controls. Secondary endpoints were response rate, overall survival (OS), and safety. RESULTS: Overall, 349 patients were randomized. PFS duration was not significantly increased in any experimental arm compared with historical controls (p > 0.039). Treatment HRs (92% CI) for Arms 1, 2, and 3 relative to controls were 0.81 (0.63-1.02), 1.22 (0.96-1.55) and 0.87 (0.68-1.11), respectively. Response rates were similar across arms (60%, 55% and 53%, respectively). Relative to controls, OS duration (with censoring at 36 months), was significantly increased in Arm 1 (p < 0.039) but not in Arms 2 and 3; the HRs (92% CIs) were 0.71 (0.55-0.91), 0.99 (0.78-1.26), and 0.97 (0.77-1.23), respectively. No new safety signals were identified. Common mutations and rates of mismatch repair protein loss are described by histotype. Potential predictive biomarkers for temsirolimus and bevacizumab were identified. CONCLUSION: PFS was not significantly increased in any experimental arm compared to historical controls. NRG Oncology/Gynecologic Oncology Group Study GOG-86P.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Aghajanian C, Filiaci V, Dizon DS, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018. PMID: 29804638. doi:10.1016/j.ygyno.2018.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。